Pacific Biosciences (PACB) CEO Mark van Oene Receives Award

What Happened

• Mark van Oene, President & CEO of Pacific Biosciences of California, Inc. (PACB), was granted awards on 2026-08-10 consisting of 489,130 restricted stock units (RSUs) and 1,967,888 derivative awards. Both grants were reported as acquisitions at $0.00 per share (reported value $0), i.e., these are compensation awards rather than cash purchases.

Key Details

• Transaction date: 2026-08-10; Form 4 filed 2026-08-11 (appears timely).
• Grants reported:
  • 489,130 RSUs @ $0.00 (footnote F1)
  • 1,967,888 derivative awards @ $0.00 (footnote F2)
• Vesting schedule (from footnotes):
  • F1: 489,130 RSUs vest in equal annual installments on Aug 10 of 2027, 2028 and 2029, subject to continued service.
  • F2: The larger award vests in 36 equal monthly installments beginning Sep 10, 2026, subject to continued service.
• Shares owned after transaction: not disclosed in this filing.
• No sale or cash exercise reported; these are compensation grants (code A — Award/Grant).

Context

• These awards are compensation-related grants to the CEO and do not represent an open-market purchase or sale. Vesting is time-based and contingent on continued service, so they do not provide immediate liquidity. Derivative/vesting schedules mean the economic interest vests over months/years rather than immediately.